Glioblastoma is a significant topic in the health domain with ongoing developments and regulatory implications.

Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.